The notices it replaced
- Reissues: PAR-18-231 National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction (U19 Clinical Trial Optional)
- 2 steps back: PAR-17-186 National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction (U19)
- 3 steps back: PAR-14-234 National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U19)
- 4 steps back: PAR-13-086 National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U19)
- 5 steps back: PAR-11-207 National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U19)
- 6 steps back: PAR-08-238 National Cooperative Drug Discovery and Development Groups (NCDDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U01/U19)
- 7 steps back: PAR-07-159
- 8 steps back: PAR-04-009
Replaced by PAR-22-144.
Who won it before
1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,072,400 in first-year total cost, median $2,072,400.
Most frequent study sections
- Special Emphasis Panel[ZMH1 ERB-C (01)]1
Most frequent institutions
- VANDERBILT UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2015 | Development of an M1 PAM experimental therapeutic for schizophrenia1U19MH106839-01 · under PAR-14-234 | CONN, P JEFFREY | VANDERBILT UNIVERSITY, TN | $2,072,400 | ZMH1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.